|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.690 CNY | +1.52% |
|
-2.58% | -13.96% |
| 06-26 | Shanghai Shyndec Pharmaceutical Gets China Regulatory Nod for Eye Drops | MT |
| 06-16 | Shanghai Shyndec Pharmaceutical Gets China Approval for Glaucoma Drops | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 4.28B | 6.15B | 5.97B | 6.21B | 4.01B | |||||
Short Term Investments | - | - | - | 1.43B | 3.06B | |||||
Total Cash And Short Term Investments | 4.28B | 6.15B | 5.97B | 7.64B | 7.06B | |||||
Accounts Receivable, Total | 3.05B | 2.66B | 2.05B | 1.36B | 1.17B | |||||
Other Receivables | 96.91M | 92.85M | 84.07M | 85.55M | 81.55M | |||||
Notes Receivable | - | - | - | - | - | |||||
Total Receivables | 3.14B | 2.75B | 2.13B | 1.45B | 1.25B | |||||
Inventory | 3.07B | 2.44B | 2.28B | 2.21B | 1.75B | |||||
Prepaid Expenses | 40.21M | 47.69M | 61.63M | 70.29M | 71.07M | |||||
Other Current Assets, Total | 345M | 300M | 207M | 315M | 1.12B | |||||
Total Current Assets | 10.89B | 11.68B | 10.66B | 11.68B | 11.25B | |||||
Gross Property Plant And Equipment | 12.52B | 12.88B | 13.05B | 13.19B | 13.2B | |||||
Accumulated Depreciation | -6.01B | -6.63B | -7.17B | -7.64B | -7.86B | |||||
Net Property Plant And Equipment | 6.51B | 6.25B | 5.88B | 5.55B | 5.34B | |||||
Long-term Investments | 371M | 376M | 1.43B | 1.32B | 1.23B | |||||
Goodwill | 160M | 160M | 160M | 160M | 160M | |||||
Other Intangibles, Total | 549M | 517M | 511M | 591M | 760M | |||||
Deferred Tax Assets Long-Term | 189M | 239M | 153M | 103M | 116M | |||||
Deferred Charges Long-Term | 145M | 228M | 332M | 334M | 227M | |||||
Other Long-Term Assets, Total | 259M | 179M | 224M | 217M | 136M | |||||
Total Assets | 19.07B | 19.63B | 19.35B | 19.96B | 19.23B | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 1.54B | 1.25B | 1.37B | 1.1B | 1.65B | |||||
Accrued Expenses, Total | 480M | 1.67B | 1.59B | 1.42B | 936M | |||||
Short-term Borrowings | 2.01B | 321M | 45.05M | 50.05M | - | |||||
Current Portion of Long-Term Debt | 540M | 48.37M | - | 1.03B | - | |||||
Current Portion of Leases | 40.13M | 9.86M | 10.6M | 8.86M | 8.85M | |||||
Current Income Taxes Payable | 30.86M | 37.94M | 29.95M | 72.51M | 44.25M | |||||
Unearned Revenue Current, Total | 1.4B | 344M | 245M | 193M | 93.81M | |||||
Other Current Liabilities | 794M | 510M | 481M | 465M | 404M | |||||
Total Current Liabilities | 6.84B | 4.2B | 3.78B | 4.34B | 3.13B | |||||
Long-Term Debt | 1.55B | 2.96B | 1.03B | - | - | |||||
Long-Term Leases | 43M | 68.57M | 57.97M | 47.94M | 33.75M | |||||
Unearned Revenue Non Current | 140M | 138M | 123M | 114M | 83.49M | |||||
Pension & Other Post Retirement Benefits | 842K | 571K | 518K | 364K | 11.41M | |||||
Deferred Tax Liability Non Current | 126M | 120M | 22.15M | 70.77M | 62.5M | |||||
Other Non Current Liabilities | - | - | - | 56.96M | 56.96M | |||||
Total Liabilities | 8.7B | 7.48B | 5.01B | 4.63B | 3.38B | |||||
Common Stock, Total | 1.03B | 1.17B | 1.34B | 1.34B | 1.34B | |||||
Additional Paid In Capital | 2.55B | 3.59B | 5.2B | 5.2B | 5.21B | |||||
Retained Earnings | 4.76B | 5.29B | 5.84B | 6.66B | 7.23B | |||||
Comprehensive Income and Other | 259M | 259M | -1.09M | -911K | -1.11M | |||||
Total Common Equity | 8.59B | 10.31B | 12.39B | 13.2B | 13.78B | |||||
Minority Interest | 1.78B | 1.85B | 1.95B | 2.12B | 2.07B | |||||
Total Equity | 10.37B | 12.15B | 14.34B | 15.32B | 15.84B | |||||
Total Liabilities And Equity | 19.07B | 19.63B | 19.35B | 19.96B | 19.23B | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 1.03B | 1.17B | 1.34B | 1.34B | 1.34B | |||||
ECS Total Common Shares Outstanding | 1.03B | 1.17B | 1.34B | 1.34B | 1.34B | |||||
Book Value / Share | 8.37 | 8.57 | 9.24 | 9.85 | 10.27 | |||||
Tangible Book Value | 7.88B | 9.63B | 11.72B | 12.45B | 12.86B | |||||
Tangible Book Value Per Share | 7.68 | 7.99 | 8.74 | 9.28 | 9.59 | |||||
Total Debt | 4.18B | 3.4B | 1.14B | 1.14B | 42.6M | |||||
Net Debt | -99.84M | -2.74B | -4.83B | -6.51B | -7.02B | |||||
Debt Equivalent of Unfunded Proj. Benefit Obligation | 1.07M | 807K | 782K | 472K | 16.33M | |||||
Debt Equivalent Oper. Leases | 453M | 231M | 236M | 178M | 141M | |||||
Minority Interest, Total (Incl. Fin. Div) | 1.78B | 1.85B | 1.95B | 2.12B | 2.07B | |||||
Equity Method Investments, Total | 145M | 150M | 156M | 169M | 194M | |||||
Account Code - Inventory Valuation | 6 | 6 | 6 | 6 | 6 | |||||
Inventories - Raw Materials, Total | 1.06B | 864M | 708M | 632M | 516M | |||||
Inventories - Work In Process, Total | 544M | 556M | 481M | 404M | 400M | |||||
Inventories - Finished Goods, Total | 1.45B | 1.02B | 1.08B | 1.19B | 844M | |||||
Inventories - Others | 86.38M | 81.24M | 85.04M | 62.46M | 47.31M | |||||
Buildings, Total | 3.87B | 3.94B | 4.47B | 4.49B | 4.38B | |||||
Machinery, Total | 7.92B | 8.18B | 8.37B | 8.45B | 8.53B | |||||
Full Time Employees | 11.94K | 11.49K | 11.61K | 11.47K | 9.7K | |||||
Assets under Capital Lease - Gross | - | - | - | - | - | |||||
Assets under Capital Lease - Accumulated Depreciation | - | - | - | - | - | |||||
Accumulated Allowance for Doubtful Accounts (Supple) | 101M | 86.54M | 68.16M | 59.48M | 63.53M |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















